cyrilzakka/clinical-trials huggingface dataset:
Foam Rolling and Tissue Flossing of the Cuff Muscles

The hypothesis is that self-myofascial release (SMR) intervention on the cuff muscles would affect positively sprint performance and jump height, as well as, decrease Achilles tendon stiffness. The second hypothesis is that tissue flossing would be more effective than foam rolling.

The participants will be randomly assigned to foam rolling, tissue flossing, and control group (without any intervention). After the intervention, repeated measures will be performed (15m sprint, countermovement jump (CMJ) and Achilles tendon stiffness). This will aim to improve sprint time, jump height and decrease tendon stiffness.

Foam rolling provides beneficial results in ankle range of motion, muscle flexibility or muscle sourness. Tissue flossing is popular in athletic training and physical therapy, as an effective strategy for ankle range of motion or performance. However, there is a lack of knowledge about the use of foam rolling and tissue flossing during a 60 minutes post-intervention examination on the performance and soft tissue stiffness.

The main aim of this study is to investigate the effect of foam rolling and tissue flossing of the cuff on sprint performance, jump height and Achilles tendon stiffness at different time points. The second aim is to assess the effectiveness of those self-myofascial release methods (SMR).

This study will include healthy, recreational active subjects aged between 20 and 25 years old.

Eligibility Criteria:
Inclusion Criteria:

* Regular physical exercise activity (\~3 times per week).

Exclusion Criteria:

* Experience with the application of foam rolling and tissue flossing.
* Current or prior pain or injury in the lower extremity.
* Previous history of surgery in the lower extremity.
* Cardiovascular disabilities.
Multiple Ascending Dose Study in Healthy Volunteers

This study will assess in healthy male and female subjects the safety, tolerability and pharmacokinetics (PK) profiles of Immediate Release CTP-730 at steady state following 7 days of dosing. Three doses of Immediate Release (IR) CTP-730 capsules will be studied.


Eligibility Criteria:
Inclusion Criteria:

* Healthy adult males and females between 18 and 50 years of age.
* Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2

Exclusion Criteria:

* Medical, psychiatric illness or history of depression that could, in the investigator's opinion, compromise the subject's safety
* Significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
* History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions.
* PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcB / QTcF interval \> 450 msec obtained at screening visit or prior to the first dose of study drug.
* Liver function tests greater than the upper limit of normal.
* Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening.
* Urinalysis positive for protein or glucose.
* A positive screen for alcohol, drugs of abuse, or tobacco use.
* Inability to comply with food and beverage restrictions during study participation.
* Donation or blood collection or acute loss of blood prior to screening.
Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger

The purpose of this study is to examine if glucocorticoids will change neural activation in regions of the corticolimbic-striatal system that regulate feeding.

The primary hypothesis tested in this study will be to determine if that in response to food cues, glucocorticoids will change neural activation in regions of the corticolimbic-striatal system that regulate feeding. It is anticipate that these changes will correlate with hunger ratings and food intake. Further, this research will also examine if glucocorticoids will increase the basal metabolic rate and alter multiple systemic appetite-regulating hormones compared to saline. It is expected that these changes will correlate positively with hunger ratings and food intake as well.

Eligibility Criteria:
Inclusion Criteria:

* BMI \< = 26 kg/m2
* Ability to read and write English

Exclusion Criteria:

* Creatinine \> 1.5
* Hgb \< 10 mg/dL
* ALT \> 2.5 x ULN
* Untreated thyroid disease
* Uncontrolled or severe hypertension
* Known neurological disorders
* Diabetes or impaired glucose tolerance
* Untreated or severe psychiatric disorders
* Malignancy
* Endogenous hypercortisolism
* Addison's disease
* Bleeding disorders
* Smoking
* Current or recent steroid use in the last 3 months
* Illicit drug use
* Eating disorders
* Drug or alcohol addiction
* History of claustrophobia
* Pregnancy
* Breastfeeding
* Contraindications to MRI
* Use of any psychoactive medication within the past 3 months
Characteristics of Long COVID-19 Syndrome

Characterization of patients with long COVID syndrome including symptoms, medical history and persistent organ damage.

Some people are very hesitant to recover from a COVID-19 infection and present persistent symptoms. The participants still suffer after the acute phase of the infection from shortness of breath, coughing, chest pain or fatigue. Therefore, a special interdisciplinary consultation was built. The consulatation is not only addressed to people who have been hospitalized due to COVID-19, but also to those with mild symptoms during infection. During the consultation hours, personal health data are collected that serves as the basis for this research project.

Eligibility Criteria:
Inclusion Criteria:

* Long COVID syndrome
* age \>= 18 years
* Informed consent

Exclusion Criteria:

* none
Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia

Dystonia is defined as a syndrome of sustained muscle contractions resulting in repetitive movements and abnormal postures. DYT1 is the most common form of genetic dystonia, but the link between genomic mutations and phenotypic expression remains largely unknown. Furthermore, secondary forms of dystonia have highlighted the role of the basal ganglia, particularly the putamen in the pathophysiology of the disease. Experimental results in a genetic model of dystonia in rodents suggest that cholinergic inter-neurons (ACh-I) of the putamen play a critical role in the pathological process of plasticity in the cortico-striatal synapse. However, these results have not been demonstrated in humans.

The purpose of this study is to demonstrate that the phenotype of dystonia is associated with the degree of striatal ACh-I alterations.

In this molecular imaging study, the investigators will directly test this hypothesis using a PET radiotracer of the vesicular acetylcholine transporter (VAT). Their goal is to explore the relationships between cholinergic dysfunction and clinical disease expression and the associated morphological and functional alterations. The experimental protocol will also include multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).

Eligibility Criteria:
Inclusion Criteria:

* Man or woman 18 to 75 years, with health insurance European health insurance card (for resident patients in EU), insurance by bilateral social security agreement signed between his country and France (for resident patients outside the EU)
* Diagnosis of dystonia DYT1 confirmed by molecular biology (TORSINE- A gene mutation)
* Patient who stopped his anticholinergic treatment 48 hours before imaging

Exclusion Criteria:

* Patients who underwent surgery for deep brain stimulation or under cholinergic treatment.
* Presence of a counter-indication for MRI
* Presence of a counter-indication for TEP Scan with \[18F\]-FEOBV
* Woman premenopausal without effective ongoing contraception (intrauterine device or combined hormonal)
* Patient who underwent a PET examination in the previous month
* Presence of any health problem preventing travel to the imaging service of the University Hospital
* Being under the legal guardianship of another person or being unable to provide consent to participate
* Pregnant or breastfeeding woman
Anastrozole and Letrozole

Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line therapy in the treatment of hormone-sensitive breast cancer. However, because these medications produce a marked reduction in serum estrogen levels, this is likely to result in an increased rate of bone loss and risk of developing osteoporosis and fractures in postmenopausal women treated with these agents. Indeed, substantial bone loss has been reported in several large clinical trials of AIs. Osteoporosis drugs are available that could prevent this loss, but they have frequent side effects and are expensive. Thus, treating all women receiving AIs might not be the most appropriate and cost-effective approach. A better approach might be to select women at highest risk of bone loss and only treat them with antiresorptive agents.

The proposed pilot study will evaluate women who receive anastrozole or letrozole therapy, are receiving adequate amounts of calcium and vitamin D and have baseline normal or moderately low bone mass in order to determine if early changes in bone turnover markers correlate with bone loss at one year. If data from this pilot protocol support our hypothesis, then we would propose a larger trial to confirm it. The ultimate aim is to predict which women are at higher risk of bone loss and therefore treat them earlier with bone-sparing agents, while those with lower risk could be monitored on conservative therapy.


Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal women with diagnosis of breast cancer - have not started Arimidex or Femara yet, but will be starting .

Exclusion Criteria:

* History of metastasis
* History of chronic kidney
* Liver GI disease
* Disorders affecting calcium metabolism
Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

This study is to evaluate effect and safety on central blood pressure with Duowell compared to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.


Eligibility Criteria:
Inclusion Criteria (All of the followings)

* 40 to 75 years old diagnosed with hypertension
* at screening, SBP ≥ 140 mmHg
* at randomization, 130 mmHg ≤ SBP ≤160 mmHg or 80 mmHg ≤ DBP ≤ 100 mmHg
* at screening, ASCVD risk ≥ 5 %
* Those who did not take the dyslipidemic medications during screening or who stopped medication for more than 2 months
* at screening, 130 mg/dL ≤ Calculated (or Measured) Serum LDL-C ≤ 190 mg/dL
* Pregnancy test negative and and who has agreed to perform effective contraception during the clinical trial

Exclusion Criteria (Any of the followings)

* known hypersensitivity to AT-1 receptor blockers or statins
* Those who are treated with secondary hypertension during screening
* Those who are being treated for malignant hypertension during screening
* Those who are taking concurrent medication that may affect blood pressure during screening
* Those who have been diagnosed with myocardial infarction or unstable angina or stroke within the last 6 months at screening
* Patients with heart failure NYHA III-IV or Left Ventricular Ejection Fraction \<40% within the last 6 months at screening
* Patients with valve disease with hemodynamically significant (over moderate degree) obstructive
* Those with known atrial fibrillation or atrioventricular conduction disturbance
* Those who show the following numerical values during the screening test

  1. CPK ≥ 3 times the normal upper limit
  2. Serum Creatinine \> 3 mg/dL
  3. Serum Potassium \> 5.5 mmol/L
  4. ALT or AST ≥ 3 times the upper normal limit
* Those with known bilateral renal artery stenosis
* Patients who underwent open heart surgery within 4 weeks prior to randomization and who had a cardiac surgery plan
* Those taking statins within 8 weeks before randomization
* Those with severe obstructive, limited or other pulmonary disease history
* Those with non-cardiac disease that can significantly shorten the expected life span to less than 2 years (eg, severe cancer)
* at screening, Anti-HIV Ab, HBsAg, HCV Ab positive
Comparison Between Ultra-narrow Diameter Implants (2,75 mm) Without Bone Regeneration Versus Standard Diameter Implants (4,3 mm) in Combination With Bone Regeneration

The main target of the study is to compare ultra-narrow diameter implants (2.75 mm) without bone regeneration versus standard diameter implants (4.3 mm) in combination with bone regeneration. To do so, patients with missing upper central incisors, canines, first or second premolars with alveolar ridges of 6 - 8 mm of thickness will be restored with dental implants. Cone beam computed tomographic examination and clinical values will be registered before and after the surgical procedure at 6 and 12 months.


Eligibility Criteria:
Inclusion Criteria:

* One missing teeth in position: upper central incisor, canine or premolar
* alveolar ridge thickness of 6 - 8 mm
* alveolar ridge height of ≥ 10 mm

Exclusion Criteria:

* Missing data
* ASA ≥ III
Comparison Between Brainlab Knee 3 Computer-assisted Navigation Systems and Conventional Instruments in TKA: a Prospective Cohort Study.

This is a a prospective cohort study. According to the inclusion criteria, volunteers were recruited from patients undergoing total knee arthroplasty. The patients are devided into two groups: the conventional TKA,the computer-assisted surgery(CAS) using Brainlab Knee 3 system.The differences of postoperative alignment,operative time,blood loss will be studied between the two groups.Clinical and functional evaluation using the scoring system of HSS(Hospital for Special Surgery) score, Western Ontario and McMaster University osteoarthritis index (WOMAC), Forgotten joint score(FJS-12) will be compared between the 2 groups,after surgery, and at the follow-up of 3 months、6 months and 12 months.

According to the inclusion criteria, patients receiving primary total knee arthroplasty were recruited and divided into two groups after doctor-patient joint decision: the traditional group underwent prosthesis placement using traditional intramedullary positioning method;The navigation group performed surgery using the Brainlab Knee 3 navigation system.Informed consent was signed after grouping. All patients were operated by the same knee prosthesis system. Both groups underwent the same procedures such as the installation of the soft tissue adjustment, prosthesis placement, wound closure and so on.All patients were given the same perioperative treatment, such as hemostasis, anti-infection and analgesia, and routine postoperative rehabilitation exercises. The full length anteroposterior and lateral radiographs of both lower extremities in weight-bearing position were taken preoperatively and one week postoperatively.The differences of postoperative alignment,operative time,blood loss will be studied between the two groups.Clinical and functional evaluation using the scoring system of HSS(Hospital for Special Surgery) score, Western Ontario and McMaster University osteoarthritis index (WOMAC), Forgotten joint score(FJS-12) will be compared between the 2 groups,after surgery, and at the follow-up of 3 months、6 months and 12 months.

Eligibility Criteria:
Inclusion criteria:

1. Patients with knee osteoarthritis who underwent primary TKA;
2. Informed consent has been signed and medical records are complete;
3. No severe varus or valgus deformity of the knee (\< 20°).

Exclusion criteria:

1. Patients undergoing revision knee replacement;
2. patients with rheumatoid arthritis and secondary knee osteoarthritis;
3. Patients with severe valgus deformity(≥ 20°);
4. Taking anticoagulant drugs for a long time in the past, or suffering from the following diseases: Renal insufficiency, liver insufficiency, severe heart disease (or coronary stent implantation within the last 12 months), severe respiratory disease, history of deep vein thrombosis in the lower extremities or a high risk of thrombosis (hereditary/acquired thrombosis), coagulation dysfunction, stroke, and malignancy
Post-Ibrutinib Colitis and Intestinal Microbiota

Identify gut microbiome biomarkers associated with colitis in patients treated with targeted therapy in hematology


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years
* Outside the context of guardianship, -affiliated to the Social Security Regime and
* Having consented to participate in the COLMI study.
* Patient who benefit of treatment by targeted therapy to Ibrutinib

Exclusion Criteria:

* History of uncontrolled colitis before the start of treatment.
* Patient with inflammatory bowel disease.
* Patient not consenting to participate.
Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone

The investigators have previously demonstrated the utility of transdermal testosterone in in vitro fertilization (IVF) low responder patients. Now, the investigators want to evaluate the efficacy of luteinizing hormone (LH) activity added to recombinant follicular stimulating hormone (FSHr) during ovarian stimulation in these patients.

Studies in macaques have indicated that androgens have some synergistic effects with follicular stimulating hormone (FSH) on folliculogenesis. Our previous clinical studies demonstrated the usefulness of pretreatment with transdermal testosterone in low-responder IVF patients.

There is controversy on the usefulness of recombinant luteinizing hormone (LHr) added to FSHr in ovarian stimulation of low responder patients. Thus, our present study has been designed to compare ovarian stimulation with FSHr alone versus LHr added to FSHr when transdermal testosterone pretreatment is used.

Eligibility Criteria:
Inclusion Criteria:

* Low responder patients: patients with previously canceled cycle or recovery of 3 or less oocytes

Exclusion Criteria:

* FSH \> 12
* Previous ovarian surgery
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of idiopathic PD according to the UK PDS Brain Bank Criteria.
2. Hoehn and Yahr stage 1, 2, or 3.
3. Screening and Baseline ESS scores \>11.

Exclusion Criteria:

1. Diagnosis of other degenerative Parkinsonian syndromes (e.g., progressive supranuclear palsy, multiple system atrophy \[MSA\], or dementia with Lewy bodies \[DLB\]).
2. Usual nightly time in bed of \<6 hours, including the night before the Baseline visit.
3. Untreated or inadequately treated moderate to severe OSA.
4. Has evidence at screening of severe cognitive impairment or has cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent.
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis

Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first to evaluate the prevalence of liver fibrosis and cirrhosis in HIV-infected patients with chronic ALT elevation and no chronic viral hepatitis using non-invasive diagnostic tests and second to find associated factors with significant fibrosis and cirrhosis. In a second longitudinal part we intend to assess fibrosis progression within 1 and 3 years.


Eligibility Criteria:
Inclusion criteria: Case patients:

* HIV-1 infection
* no hepatitis B and C coinfection
* chronic alanine aminotransferase (ALT) elevation after 1.1.2007
* signed informed consent
* no other common cause of liver disease

Control patients:

* HIV-infection
* no hepatitis B and C coinfection
* no ALT elevation after 1.1.2002, the date when ALT values were regularly collected in the Swiss HIV Cohort Study (SHCS)
* no known chronic liver disease

Exclusion criteria: please see inclusion criteria
Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation

The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural hematoma. The main questions it aims to answer are:

* Does anticoagulation resumption 5 days after surgery as compared to 30 days after surgery result in fewer thromboembolic complications, without increasing the risk for bleeding?
* Does anticoagulation resumption 5 days after surgery as compared to 30 days after surgery affect the risk of reoperation, functional outcome, mortality, and healthcare use?

Researchers will compare early anticoagulation resumption (5 days) and late anticoagulation resumption (30 days) after chronic subdural hematoma surgery.

Participants will either resume the medication 5 days or 30 days after the surgery. The participants will be followed up for 3 months after the surgery.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years.
* Patients with a symptomatic unilateral or bilateral CSDH requiring burr-hole evacuation with drainage (CSDH is predominantly hypodense or isodense on imaging \[CT/MRI\]; clinical symptoms attributable to the CSDH; patients with bilaterally operated CSDHs will be treated with the same protocol on both sides and analyzed as a single study participant).
* Patients that are on an oral anticoagulation medication due to permanent, persistent or paroxysmal spontaneous atrial fibrillation previously known
* Randomization done within 4 days of the surgery

Exclusion Criteria:

* Intraoperative or immediate postoperative hemorrhagic complication
* CSDH requiring surgical treatment other than burr-hole evacuation (e.g. craniotomy)
* Prior CSDH surgery within 12 months
* Cerebrospinal fluid shunt
* CSDH is in an arachnoid cyst
* If the operated hematoma is revealed to be a cerebrospinal fluid collection (hygroma)
* Conditions other than atrial fibrillation that require anticoagulation, including therapeutical dose of low molecular-weight heparin or heparin (for example, pulmonary embolism, deep vein thrombosis, hypercoagulability syndromes)
* Mechanical heart valve(s)
* Moderate or severe mitral stenosis (other valvular diseases and biological valves are eligible)
* Contraindication to anticoagulation medication (for example bleeding disorder, documented high risk of fall \[e.g. due to severe alcoholism\], severe thrombocytopenia, severe anemia)
* Concomitant use of antiplatelet medication
* Moderate to severe renal insufficiency (creatinine clearance \<30 ml/min or on dialysis)
* Not a permanent resident in Finland (for Finnish patients) or not a permanent resident in Region Stockholm (for Swedish patients)